Pear Therapeutics’ reSET and reSET-O prescription digital therapeutics can be found to Florida’s 5 million Medicaid sufferers by way of its Most popular Drug Listing as of this month.
Pear’s reSET, a cellular software used to assist deal with substance abuse, obtained FDA De Novo clearance in 2017. The Boston-based firm’s reSET-O, used for opioid use dysfunction, obtained 510(ok) clearance in 2018.
“The unmet want in habit throughout the U.S. is gigantic, and Florida represents an essential step in how we’re serving to an increasing number of sufferers by working with states to supply lined entry to our merchandise,” Julia Strandberg, chief industrial officer of Pear Therapeutics, stated in an announcement.
THE LARGER TREND
In November, Pear entered right into a contract with the Wisconsin Division of Well being Companies to supply its reSET and reSET-O prescription digital therapeutics to taking part suppliers throughout the state’s outpatient therapy settings, together with packages that present prescriptions for buprenorphine, a medication used to deal with opioid dependence.
Earlier this month, Spero Well being introduced its 99 outpatient substance abuse facilities all through Kentucky, Ohio, Indiana, Tennessee, Virginia and West Virginia would acquire entry to reSET and reSET-O.
The corporate was additionally awarded a contract from the California Division of Healthcare Companies to assist the implementation of a pilot program that gives motivational incentives to people with stimulant use dysfunction.
The publicly-traded firm wasn’t resistant to the numerous layoffs seen all through the digital well being sector final summer time.
In July, Pear laid off roughly 25 of its staff, making up about 9% of its full-time workforce, as a result of bigger financial atmosphere and the necessity to restructure operations to slender its short-term enterprise focus.
The layoff announcement got here three months after Pear launched a program to supply its reSET and reSET-O choices by way of telehealth suppliers. The primary was Pursue Care, which focuses on habit drugs.
